viewAstraZeneca PLC

South Africa stops use of AstraZeneca vaccine due to new variant worries

The AstraZeneca vaccine and the alternative developed by Pfizer/BioNTech both work very well against the original form of Covid-19.

AstraZeneca -

Concerns about the effectiveness of AstraZeneca PLC’s (LON:AZN) against new variants of coronavirus grew today as South Africa stopped administering the drug.

New research indicated the vaccine gave little protection against mild infections in young people of the so-called South African variant, though it did better against more severe infections.

The study of the South African variant, at the Witwatersrand and Oxford universities, showed the risk of catching a mild or moderate bout of Covid-19 was just 22% lower among those taking the vaccine than in people taking a placebo.

Professor Shabir Madhi, lead investigator on the AstraZeneca trial told the BBC it would still prevent serious illness or death especially as introduced severe disease by 89%,

“There’s still some hope that the AstraZeneca vaccine might well perform as well as the Johnson & Johnson vaccine in a different age group demographic,” he said in a radio interview.

Evidence so far is that the AstraZeneca vaccine and the alternative developed by Pfizer/BioNTech both work very well against the original form of Covid-19.

“There is no evidence that this vaccine is not effective in preventing hospitalisation and severe illness and death, which ultimately is what we’re seeking with these vaccines today,” Edward Argar, junior health minister, told Sky.

Pfizer’s vaccine though is also thought to effective against some of the new variants.

So far, the UK has given more than 12mln Britons a dose of one or other of these two vaccines, but over the weekend ministers said booster shots might be needed to deal with the virus as it evolves.

“It would be just be normal in a sense as we did with the flu vaccine to update it to catch anything the virus is trying to do to keep ahead of it,” Argar said.

So far, only 147 people in the UK has registered positive for the South African but it is much more contagious than earlier forms and   the fear is that actual infections might be much higher.

Quick facts: AstraZeneca PLC


Price: 8063 GBX

Market Cap: £124.91 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Hochschild Mining reveals 'profitable' PEA on its heavy rare earths project...

Hochschild Mining Head of Investor Relations Charles Gordon joined Proactive New York to discuss the Peru-based gold and silver miner's recent developments within its heavy rare earths project, recently renamed Aclara. Gordon says the group recently revealed a preliminary economic assessment...

1 day, 5 hours ago

2 min read